Clinical trial report stirs debate.
Glenn
G
Magee
Liza G
LG
Ovington
D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use; D000077214:Becaplermin; D018592:Cross-Over Studies; D017719:Diabetic Foot / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use; D020574:Proto-Oncogene Proteins c-sis; D011758:Pyrroles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D012107:Research Design / Q000592:standards*; D014753:Vinyl Compounds / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects
D043925:Angiogenesis Inducing Agents; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011758:Pyrroles; D014753:Vinyl Compounds; C118676:poly(divinyl-co-N-vinylpyrrolidinone); D000077214:Becaplermin